Lilly's CrossBridge Bet: Does a $300M Dual-Payload ADC Deal Signal Obsolescence Risk for Today's TROP2 Leaders?
Eli Lilly pays up to $300M for a pre-clinical startup with zero human data. We are launching primary research to determine what that price tag reveals about the competitive ceiling on single-payload TROP2 ADCs from AstraZeneca, Daiichi Sankyo, and Gilead.